Company Profile

Three advantages in obtaining EME antibodies

1. Ultra-fast screening in as little as 30 business days: "The Month"

We have developed a fully in vitro, high-speed screening system. We can provide hit sequences with excellent target binding properties in just 30 business days.

2. Addressing difficult-to-target (membrane proteins)

Antibodies can be obtained against various types of targets. Screening is supported not only with recombinant antigens but also with expressing cells.

3. Animal-free antibody acquisition

Since the entire process is completed in vitro, it is possible to design the system with ESG compliance in mind. Data can also be provided. This enables free exploration unconstrained by immunology.

About Us

Message from CEO

In the fields of next-generation drug discovery and biochemical materials, the ability to quickly and reliably obtain superior antibodies and peptides is a crucial factor that determines the success or failure of a project.
I have dedicated many years to the study of evolutionary molecular engineering. Within that context, I developed our "cDNA display technology" to overcome the limitations of conventional animal immunization and phage display methods, and to bring innovation to the field of functional materials, including drug discovery.
EME's services go beyond simply providing screening services. Highly specialized Ph.D. researchers gathered in Saitama University's cutting-edge labs are deeply committed to our clients' target proteins and challenges, creating high-quality lead molecules at an overwhelming speed of as little as 30 business days.
We aspire to be the best technology partner for drug discovery researchers and applied chemistry researchers around the world, supporting the social implementation of next-generation modalities.

Epsilon Molecular Engineering Co., Ltd.
Naoto Nemoto, President and Representative Director

Biography

1996

Completed doctoral program in Biological and Environmental Sciences, Graduate School of Science and Engineering, Saitama University. Doctor of Philosophy (Academic).
Special Researcher, Mitsubishi Chemical Life Science Institute, Inc.

1999

Senior Researcher, Gencom Co., Ltd.

2003

BioVision Capital Co., Ltd. Director, Head of Research Planning
Visiting Researcher, Venture Development Strategy Research Center, National Institute of Advanced Industrial Science and Technology (AIST)

2006

Genesis Co., Ltd. Executive Officer and Chief Scientific Officer

2008

Associate Professor, Department of Materials Science, Graduate School of Science and Engineering, Saitama University

2015

Professor, Department of Materials Science, Graduate School of Science and Engineering, Saitama University

2016

Director, EME Co., Ltd.

2017

EME Co., Ltd. Representative Director

Science and technology advisor

• 

  Yuzuru Fushimi

  Professor Emeritus, Saitama University; Director of Advanced Measurement Development, Japan Science and Technology Agency
  • molecular biophysics
  • evolutionary molecular engineering
  • Biomeasurement

  He began his research on experimental molecular evolution at Saitama University. After studying abroad at the Max Planck Institute, he developed "CellStat," which forms the basis of evolutionary molecular engineering. He named mRNA-nascent protein conjugates "in vitro viruses" and further developed the theory of protein evolution in vitro.

• 

  Junichi Nakai

  Professor Emeritus, Tohoku University; Professor Emeritus, Saitama University
  • molecular physiology
  • Neurophysiology
  • fluorescence imaging

  After working as an internist, I transitioned to research in molecular biology and physiology. In 2001, I developed a fluorescent calcium sensor molecule (G-CaMP) that reacts to calcium ions, and I am currently conducting research to elucidate cellular functions using fluorescence imaging in vivo.

• 

  Yasushi Kubo

  Science Fellow, Glycotechnology Research Institute Co., Ltd.
  ProteoBridge Co., Ltd. Director and CTO
  • Neuromolecular physiology
  • Peptide Engineering
  • In vitro evolution

  Having honed his skills in the physiological biochemistry and molecular biology of peptides and proteins, he held positions at institutions such as the National Institute of Advanced Industrial Science and Technology (AIST) before assuming his current position. Building upon his research into naturally occurring bioactive peptides, he entered the field of in vitro evolution, pursuing research that emphasizes the joy of creating new molecules and the potential for social contribution.

• 

  Takuya Terai

  Associate Professor, Graduate School of Science, The University of Tokyo
  • Chemical biology
  • photofunctional molecules
  • Protein Engineering

  Graduated from the Faculty of Pharmaceutical Sciences, University of Tokyo, with a PhD in Pharmaceutical Sciences. Engaged in the development of photo-functional molecules, including fluorescent sensors, drug discovery through small molecule screening, and the exploration of functional polypeptides using evolutionary molecular engineering. Leveraging this expertise, she contributes to EME's technological development.

• 

  Kenzo Fujimoto

  Professor, Japan Advanced Institute of Science and Technology (JAIST)
  • Nucleic acid drugs
  • RNA editing
  • Ultrafast DNA optical manipulation

  He holds a PhD in Engineering from Kyoto University Graduate School. His work focuses on developing DNA/RNA manipulation methods using uniquely designed photoresponsive molecules, leading the development of technologies for photo-controlled intracellular gene expression and light-based RNA editing. Leveraging his expertise in nucleic acid chemistry and other related fields, he advises EME on peptide drug discovery.

• 

  Kosuke Matsunaga

  Associate Professor, Graduate School of Science and Engineering, Saitama University
  • computational biology
  • Molecular dynamics
  • Machine learning

  Completed doctoral program at Kobe University Graduate School of Science in 2007, PhD (Science). Engaged in molecular dynamics simulations of biomolecules and molecular modeling utilizing machine learning. Leveraging expertise in computational science and AI-based dry methods, I provide advice on data analysis and sequence optimization.

History

Access

Electronic Public Notice

In accordance with the law, we hereby publish our financial statements and other advertising information.

Intellectual Property and Confidentiality Policy

Flexible intellectual property strategies and co-creation

In joint research and partnerships, we respect each other's expertise and flexibly discuss and decide on the optimal ownership of rights (sharing, transfer, exclusive use, etc.) based on the degree of contribution and business model.

Responding to the transfer of rights to deliverables

In our contracted services, we prioritize maximizing our clients' business competitiveness when it comes to the rights to deliverables. Depending on the nature of the project, we will propose a contract structure that is tailored to your business, including the option of 100% rights transfer.

Strict information management and confidentiality

Confidential information entrusted to us and knowledge gained from collaborative research will be strictly managed through organizational and technical measures. All employees are bound by confidentiality obligations, and we will thoroughly prevent their use for purposes other than those intended or their disclosure to third parties.

Compliance with laws and contracts

We will comply with relevant laws and regulations, including the Unfair Competition Prevention Act, and the confidentiality agreements (NDAs) we have signed, and promote honest business activities with a high level of ethical awareness befitting a university-based venture company.